Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-DaroRT: SBRT + Darolutamide + ADT in Metastatic Hormone-Sensitive Prostate Cancer
NCT07649421Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Radiographic Progression-Free Survival at 3 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07649421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649421.